Abbott officially launches new production line for anti-cancer drugs in Russia

The USA’s Abbott Laboratories (NYSE: ABT) has officially launched a new line for the production of anti-cancer drugs at the facilities of its Russian Veropharm subsidiary in the Belgorod region, reports The Pharma Letter’s local correspondent.

The new line was equipped and launched in accordance with Good Manufacturing Practice (GMP) standards and is part of a large-scale modernization program of the plant launched in 2016, with the total costs of more than 3 billion roubles ($48 million).

Under the terms of the project, the company will produce six anti-cancer drugs for the treatment of leukemia, and breast cancer, gastric, prostate and other cancers. Products from the plant will be appearing on the domestic market already at the beginning of next year.